Mizuho Maintains Buy on Axsome Therapeutics, Raises Price Target to $95

Benzinga · 05/11/2023 06:52
Mizuho analyst Graig Suvannavejh maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises the price target from $84 to $95.